| ATHENS,
Greece)--July 1, 2005--Acrongenomics
Inc. is pleased to announce the launch of its Nano-JETA(TM)
Real Time PCR Pilot kits for DNA/RNA quantification
with the use of beta-globin and Ep-CAM gene, respectively.
The results obtained from
previous validation and
comparative studies bring
Acrongenomics one step
closer to finalizing its
Nano-JETA(TM) technology
platform by introducing
its first Real Time PCR
prototype kits. The kits
apply to scientific professionals
for demonstration purposes
only in order for the company
to obtain scientific feedback
that will enhance the product's
usability and will establish
the Nano-JETA(TM) platform.
The DNA/RNA quantification
with the Nano-JETA(TM)
technology platform is
based on Acrongenomics'
new mathematical model.
Furthermore, Nano-JETA(TM)
Real Time PCR delivers
rapid quantitative detection
of nucleic acids from the
2nd cycle up to the 13th
cycle.
Any Real Time PCR thermocycler
with specifications to
transmit fluorescence data
according to Acrongenomics'
mathematical model is now
able to quantify DNA/RNA
copies at any point between
the 2nd and 13th cycle.
The pilot kits allow for
24 tests to be performed.
Furthermore, the kits contain:
-- Certificate of Analysis
(COA)
-- Comprehensive Manual
-- General Mix (GM)
-- Pre-Mix1 (PM1)
-- Nano-JETA Master Mix
(NJMM)
-- New mathematical model
required for quantification
from the 2nd cycle.
Since last year, the Nano-JETA(TM)
technology platform by
Acrongenomics Inc. has
redefined key IVD molecular
applications such as PCR,
ELISA and Real Time PCR
giving them super fast
characteristics with up
to 100% specificity and
sensitivity.
Currently, Acrongenomics
is working towards the
enrichment of its portfolio
with prototype kits for
detection and quantification
of additional tumor markers
expression such as the
HER family and vEGF, as
well as for viral quantification
with markers such as EBV,
HBV and HPV.
Molecular
diagnostics testing is
the fastest-growing segment
of the in vitro diagnostics
industry. The last four
years, clinical market
for molecular diagnostic
products has increased
from $1 billion in 2000
to $2.8 billion in 2004
and sales are expected
to exceed $5 billion by
2008 (Biotechnology Associates).
More interestingly, D & MD's
nanobiotechnology briefing
states that the overall
market impact of nanobiotech
applications is projected
to reach $300 billion US
by 2020.
Acrongenomics Inc. is
a Research and Development
nanobiotechnology company
specializing in the development
of ground-breaking nanomolecular
diagnostic tools to diagnose
various diseases such as
cancer of epithelial origin.
Acrongenomics Inc.
Investor Relations
Tom Skarpelos
1-800-689-8181
info@acrongen.com
www.acrongen.com
|
